Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW4YK1)

• Drug Name: Remogliflozin etabonate Drug Info
• Synonyms: GSK-189075; GSK-189075A; KGT-1681

Indication

Disease Entry	ICD 11	Status	REF
Type-1/2 diabetes	5A10-5A11	Phase 2	[1]
Type-2 diabetes	5A11	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 9871420
  ChEBI ID: CHEMBL2028665
  CAS Number: CAS 442201-24-3
  TTD Drug ID: DMW4YK1
  VARIDT Drug ID: DR01037

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium/glucose cotransporter 2 (SLC5A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[4]
RG7201	DMJRFYB	Type-2 diabetes	5A11	Phase 3	[5]
Remogli ozin-etabonate	DMZFV3E	Type-2 diabetes	5A11	Phase 2	[6]
Ponalrestat	DM04ZUW	Gout	FA25	Discontinued in Phase 3	[7]

Drug(s) Targeting Sodium/glucose cotransporter 2 (SGLT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dapagliflozin	DM28UJG	Non-insulin dependent diabetes	5A11	Approved	[8]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[8]
Canagliflozin	DMFRM1I	Non-insulin dependent diabetes	5A11	Approved	[9]
PF-04971729	DM79VXT	Type-2 diabetes	5A11	Approved	[10]
Sotagliflozin	DMMLXA9	Heart failure	BD10-BD13	Approved	[11]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[12]
ASP1941	DMGQ1TV	Liver disease	DB90-BD99	Phase 3	[13]
LIK-066	DM32NWD	Heart failure	BD10-BD13	Phase 2	[14]
AVE-2268	DMA42BV	Diabetic complication	5A2Y	Phase 2	[15]
YM-543	DMRZBPI	Type-2 diabetes	5A11	Phase 2	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium/glucose cotransporter 2 (SGLT2)	TTLWPVF	SC5A2_HUMAN	Inhibitor	[2]
Sodium/glucose cotransporter 2 (SLC5A4)	TTN7Y4P	SC5A4_HUMAN	Blocker	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021813)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [4] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [5] Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65.
• [6] Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25.
• [7] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [8] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [9] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [10] Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8.
• [11] LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.
• [16] Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183.